DocStoX is a free AI-powered research platform for Indian equity markets, covering 5,700+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (5,700+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 94 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

Positive impactResults

Stocks in news: BSE, Lenskart, Nykaa, Bharti Airtel, LIC, Aurobindo Pharma and Nalco

Economic Times 1 hr ago·5 Nov 2026, 12:30 am

Aurobindo Pharma has emerged as a key highlight in the current market rally, driven by strong earnings performance. The company recently reported a robust set of numbers, which has caught the attention of investors looking for quality growth in the pharmaceutical sector. This positive result signals that the company's operational momentum remains intact, even as the broader market navigates a period of volatility.

For investors, this development is significant because it reinforces the strength of the pharma sector amidst broader market gains. A strong earnings report typically boosts investor confidence and can lead to a re-rating of the stock. However, as the market approaches key resistance levels, it is important to monitor the stock's price action closely to see if the uptrend can sustain itself.

Excerpt from Economic Times

Indian equity markets have enjoyed a remarkable stretch, registering gains for five consecutive sessions. The Nifty 50 index showed impressive growth, sparking optimism for a breakout beyond 24,000. Companies like Lenskart, Aurobindo Pharma, and BSE are in the spotlight as they report positive earnings. Experts advise…

Read the original at Economic Times

Affected stocks

Bullish6 stocks

Aurobindo Pharma

₹1,705.00

BHARTIARTL

—

LENSKART

—

NATIONALUM

—

NYKAA

—

LICI

—

Bull / bear label is derived from the article's AI sentiment — indicative, not advice. Prices may be delayed.

Key takeaways

Concerns Aurobindo Pharma (AUROPHARMA).
Category: Results.
AI reads the tone as positive (potentially bullish) for the stock.
Assessed as a significant, market-relevant update.
Also mentions BHARTIARTL, LENSKART, NATIONALUM.

Why it matters

A meaningful update for Aurobindo Pharma worth tracking. The tone is positive — historically associated with upward pressure, though not predictive. Use the price and stock snapshot to gauge how the market is responding.

Summary & analysis by DocStoX. Full story at Economic Times.